Skip to main content
Learn How to Analyze Your Market and Trading Plan
Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.
Download Your FREE Options Trading Strategy Guide today!
pixel

KRON Insider Trading (Kronos Bio)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $10,514,220.00
Insider Selling (Last 12 Months): $3,875,475.10

Kronos Bio Insider Trading History Chart

Kronos Bio Share Price & Price History

$24.80
▼ -0.57 (-2.25%)
As of 05/14/2021 01:00 AM ET
Days: 30 | 90 | 365
Learn How to Analyze Your Market and Trading Plan
Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.
Download Your FREE Options Trading Strategy Guide today!
pixel

Kronos Bio Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/19/2021Jakob LovenDirectorSell14,004$20.59$288,342.36View SEC Filing Icon  
4/16/2021Jakob LovenDirectorSell33,162$21.01$696,733.62View SEC Filing Icon  
4/14/2021Jakob LovenDirectorSell32,636$22.80$744,100.80View SEC Filing Icon  
4/12/2021Jakob LovenDirectorSell15,828$26.28$415,959.84View SEC Filing Icon  
4/8/2021Jakob LovenDirectorSell63,128$27.41$1,730,338.48View SEC Filing Icon  
10/14/2020Barbara KosaczCOOBuy5,250$19.00$99,750.00614,600View SEC Filing Icon  
10/14/2020Elena RidloffDirectorBuy2,630$19.00$49,970.002,630View SEC Filing Icon  
10/14/2020Fund V L.P. OmegaMajor ShareholderBuy450,000$19.00$8,550,000.002,437,662View SEC Filing Icon  
10/14/2020Norbert W BischofbergerCEOBuy95,500$19.00$1,814,500.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Kronos Bio (NASDAQ:KRON)

Institutional Buying and Selling by Quarter

Kronos Bio Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/14/2021TD Asset Management Inc.32,837$0.96M0.0%+10.9%0.059%Search for SEC Filing on Google Icon
5/14/2021UBS Asset Management Americas Inc.151,634$4.44M0.0%N/A0.270%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp38,605$1.13M0.0%+3.3%0.069%Search for SEC Filing on Google Icon
5/13/2021Citigroup Inc.1,486$43K0.0%-46.2%0.003%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp162,258$4.75M0.0%-4.5%0.289%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC268,920$7.87M0.0%+6.9%0.480%Search for SEC Filing on Google Icon
5/12/2021Ensign Peak Advisors Inc451,169$13.21M0.0%+110.9%0.805%Search for SEC Filing on Google Icon
5/12/2021JPMorgan Chase & Co.1,623,038$47.51M0.0%+1.1%2.895%Search for SEC Filing on Google Icon
5/11/2021New York State Common Retirement Fund13,200$0.39M0.0%+15.8%0.024%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.1,635,564$47.87M0.0%+7.1%2.917%Search for SEC Filing on Google Icon
5/6/2021Rhumbline Advisers15,190$0.45M0.0%+15.5%0.027%Search for SEC Filing on Google Icon
5/4/2021Victory Capital Management Inc.1,059,066$31M0.0%+58.9%1.889%Search for SEC Filing on Google Icon
3/2/2021Norges Bank15,000$0.45M0.0%N/A0.027%Search for SEC Filing on Google Icon
2/24/2021Alyeska Investment Group L.P.100,000$2.99M0.0%N/A0.178%Search for SEC Filing on Google Icon
2/19/2021JPMorgan Chase & Co.1,604,761$47.93M0.0%N/A2.864%Search for SEC Filing on Google Icon
2/17/2021Samsara BioCapital LLC166,250$4.97M0.5%N/A0.297%Search for SEC Filing on Google Icon
2/17/2021Ratan Capital Management LP23,278$0.70M0.1%N/A0.042%Search for SEC Filing on Google Icon
2/16/2021Alyeska Investment Group L.P.100,000$2.99M0.0%N/A0.178%Search for SEC Filing on Google Icon
2/16/2021Nuveen Asset Management LLC53,295$1.59M0.0%N/A0.095%Search for SEC Filing on Google Icon
2/16/2021Price T Rowe Associates Inc. MD2,113,578$61.75M0.0%N/A3.772%Search for SEC Filing on Google Icon
2/16/2021Charles Schwab Investment Management Inc.91,341$2.73M0.0%N/A0.163%Search for SEC Filing on Google Icon
2/13/2021Hillhouse Capital Advisors LTD.658,436$19.67M0.2%N/A1.175%Search for SEC Filing on Google Icon
2/13/2021American International Group Inc.8,494$0.25M0.0%N/A0.015%Search for SEC Filing on Google Icon
2/13/2021Vida Ventures Advisors LLC2,765,314$82.60M17.0%N/A4.935%Search for SEC Filing on Google Icon
2/12/2021Caas Capital Management LP15,000$0.45M0.0%N/A0.027%Search for SEC Filing on Google Icon
2/12/2021Laurion Capital Management LP10,000$0.30M0.0%N/A0.018%Search for SEC Filing on Google Icon
2/12/2021The Manufacturers Life Insurance Company8,416$0.25M0.0%N/A0.015%Search for SEC Filing on Google Icon
2/11/2021Northern Trust Corp169,827$5.07M0.0%N/A0.303%Search for SEC Filing on Google Icon
2/11/2021Citigroup Inc.2,760$82K0.0%N/A0.005%Search for SEC Filing on Google Icon
2/11/2021Artal Group S.A.1,317,954$39.37M0.8%N/A2.352%Search for SEC Filing on Google Icon
2/10/2021Rhumbline Advisers13,156$0.39M0.0%N/A0.023%Search for SEC Filing on Google Icon
2/10/2021HighTower Advisors LLC15,000$0.45M0.0%N/A0.027%Search for SEC Filing on Google Icon
2/9/2021Wells Fargo & Company MN7,577$0.23M0.0%N/A0.014%Search for SEC Filing on Google Icon
2/9/2021Bank of New York Mellon Corp37,367$1.12M0.0%N/A0.067%Search for SEC Filing on Google Icon
2/8/2021Blackhill Capital Inc.8,500$0.25M0.0%N/A0.015%Search for SEC Filing on Google Icon
2/8/2021New York State Common Retirement Fund11,400$0.34M0.0%N/A0.020%Search for SEC Filing on Google Icon
2/5/2021BlackRock Inc.1,526,688$45.60M0.0%N/A2.725%Search for SEC Filing on Google Icon
2/1/2021Victory Capital Management Inc.666,437$19.91M0.0%N/A1.189%Search for SEC Filing on Google Icon
1/25/2021Strs Ohio3,600$0.11M0.0%N/A0.006%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Kronos Bio logo
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Read More on Kronos Bio

Today's Range

Now: $24.80
$24.53
$26.87

50 Day Range

MA: $25.76
$20.08
$29.27

52 Week Range

Now: $24.80
$19.60
$39.60

Volume

214,657 shs

Average Volume

180,839 shs

Market Capitalization

$1.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Kronos Bio?

Kronos Bio's top insider investors include:
  1. Fund V LP Omega (Major Shareholder)
  2. Barbara Kosacz (COO)
  3. Elena Ridloff (Director)
  4. Jakob Loven (Director)
  5. Norbert W Bischofberger (CEO)

Who are the major institutional investors of Kronos Bio?

Kronos Bio's top institutional investors include:
  1. BlackRock Inc. — 2.92%
  2. JPMorgan Chase & Co. — 2.89%
  3. Victory Capital Management Inc. — 1.89%
  4. Ensign Peak Advisors Inc — 0.80%
  5. Geode Capital Management LLC — 0.48%
  6. Northern Trust Corp — 0.29%

Which major investors are selling Kronos Bio stock?

In the last quarter, KRON stock was sold by these institutional investors:
  1. Northern Trust Corp
  2. Citigroup Inc.

Which major investors are buying Kronos Bio stock?

Within the previous quarter, KRON stock was acquired by institutional investors including:
  1. Victory Capital Management Inc.
  2. Ensign Peak Advisors Inc
  3. UBS Asset Management Americas Inc.
  4. BlackRock Inc.
  5. JPMorgan Chase & Co.
  6. Geode Capital Management LLC
  7. TD Asset Management Inc.
  8. Rhumbline Advisers
During the last year, these company insiders have bought Kronos Bio stock:
  1. Fund V LP Omega (Major Shareholder)
  2. Barbara Kosacz (COO)
  3. Elena Ridloff (Director)
  4. Jakob Loven (Director)
Learn How to Analyze Your Market and Trading Plan
Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.
Download Your FREE Options Trading Strategy Guide today!
pixel